1. Figure 1 Somatic and germ-line TP53 mutations in cancer
Figure 1 | Somatic and germ-line TP53 mutations in cancer. a | Overview of cancer types associated with TP53 mutations. The inner yellow area shows the anatomical sites of cancers that are prevalent in individuals with Li–Fraumeni syndrome (LFS) who have germ-line TP53 mutations. The majority of the cancers (80%) associated with LFS occur at the sites highlighted in the top part of the yellow area. The blue area shows the locations of cancers with somatic TP53 mutations, which also include all sites of neoplasia associated with LFS (as indicated by the fact the yellow area is completely encompassed within the blue area in this diagram). Sites of sporadic cancers with a >30% or <30% frequency of somatic TP53 mutations are highlighted in green and white boxes, respectively. Interestingly, the sporadic counterparts of the cancers predominantly associated with LFS (top half of the yellow area) all have a <30% frequency of somatic TP53 mutations. Data from the IARC TP53 database were used to formulate this schematic summary4. b | Schematic cartoon showing the domain structure of the p53 protein. The aligned graphs indicate the relative frequency of missense mutations across the domains of p53, based on data for 1,509 tumours associated with germ-line TP53 mutations and 27,852 sporadic tumours from the IARC TP53 database (R18, v2016)4. CTD, carboxyl-terminal domain; DBD, DNA-binding domain; IARC, International Agency for Research of Cancer; OD, oligomerization domain; PR, proline-rich doman; TA, transactivation domain. Adapted with permission from the IARC.
Adapted with permission from the IARC.
Sabapathy, K. & Lane, D. P. (2017) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Nat. Rev. Clin. Oncol. doi: /nrclinonc